How accurately could we screen for individual risk? Using summary data to examine discriminatory accuracy of a risk marker

Preventive Medicine

Volumn 45, Issue 5, 2007, Pages 342-347

  Levine, Beverly J ^a   Levine, Douglas W ^a  

^a UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

Discrimination; Prevention and control; Risk; Screening; Statistics

Indexed keywords

ARTICLE; DIAGNOSTIC ACCURACY; DISEASE COURSE; FALSE POSITIVE RESULT; HUMAN; MATHEMATICAL MODEL; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS;

BIOLOGICAL MARKERS; HUMANS; MASS SCREENING; MODELS, THEORETICAL; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 35648987995     PISSN: 00917435     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ypmed.2007.07.015     Document Type: Article

References (29)

1. Baldwin L., Klabunde C., Green P., Barlow W., and Wright G. In search of the perfect comorbidity measure for use with administrative claims data: does it exist?. Med. Care 44 (2006) 745-753
2. Bamber D. The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. J. Math. Psychol. 12 (1975) 387-415
3. Barlow W., White E., Ballard-Barbash R., et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J. Natl. Cancer Inst. 98 (2006) 1204-1214
4. Beskow L.M., Khoury M.J., Baker T.G., and Thrasher J.F. The integration of genomics into public health research, policy and practice in the United States. Community Genet. 4 (2001) 2-11
5. Bradbury A., and Olopade O. The case for individualized screening recommendations for breast cancer. J. Clin. Oncol. 24 (2006) 3328-3330
6. Brand T., Canby-Hagino E., Kumar A.P., Ghosh R., Leach R., and Thompson I. Chemoprevention of prostate cancer. Hematol./Oncol. Clin. North Am. 20 (2006) 831-843
7. Collins F.S. Shattuck lecture: medical and societal consequences of the human genome project. New Engl. J. Med. 341 (1999) 28-36
8. Collins F.S., Green E.D., Guttmacher A.E., and Guyer M.S. A vision for the future of genomics research. Nature 422 (2003) 1-13
9. Gail M., and Pfeiffer R. On criteria for evaluating models of absolute risk. Biostatistics 6 (2005) 227-239
10. Gail M., Brinton L., Byar D., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. 81 (1989) 1879-1886
11. Grant S.F.A., Thorleifsson G., Reynisdottir I., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Gen. Adv. Online Publ. (2006) 1-4 10.1038/ng1732
12. Green D., and Swets J. Signal Detection Theory and Psychophysics (1966), John Wiley and Sons, New York
13. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
14. Harrell Jr. F.E. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis (2001), Springer-Verlag New York Inc., New York
15. Khoury M.J., McCabe L.L., and McCabe E.R.B. Population screening in the age of genomic medicine. New Engl. J. Med. 348 (2003) 50-58
16. Khoury M.J., Yang Q., Gwinn M., Little J., and Flanders W.D. An epidemiologic assessment of genomic profiling for measuring susceptibility to common diseases and targeting interventions. Gen. Med. 6 (2004) 38-47
17. Manenti E., Bodanese L., Camey S., and Polanczyk C. Prognostic value of serum biomarkers in association with TIMI risk score for acute coronary syndromes. Clin. Cardiol. 29 (2006) 405-410
18. Moses L.E. Think and Explain with Statistics (1986), Addison-Wesley, Reading, Massachusetts
19. Narayan K.M.V., Boyle J.P., Thompson T.J., Sorensen S.W., and Williamson D.F. Lifetime risk for diabetes mellitus in the United States. JAMA 290 (2003) 1884-1890
20. Pepe M., Cai T., and Longton G. Combining predictors for classification using the area under the receiver operating characteristic curve. Biometrics 62 (2006) 221-229
21. Pharoah P.D.P., Antoniou A., Bobrow M., Zimmern R.L., Easton D.F., and Ponder B.A.J. Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31 (2002) 33-36
22. Pritchard J.K. Are rare variants responsible for susceptibility to complex diseases?. Am. J. Hum. Genet. 69 (2001) 124-137
23. Rockhill B. The privatization of risk. Am. J. Pub. Health 91 (2001) 365-368
24. Rockhill B., Spiegelman D., Byrne C., Hunter D., and Colditz G. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J. Natl. Cancer Inst. 93 (2001) 358-366
25. Tice J., Miike R., Adduci K., Petrakis N., King E., and Wrensch M. Nipple aspirate fluid cytology and the Gail model for breast cancer risk assessment in a screening population. Cancer Epidemiol. Biomark. Prev. 14 (2005) 324-328
26. Wade N. Gene increases diabetes risk, scientists find (2006), New York Times, New York 1
27. Wald N.J., Hackshaw A.K., and Frost C.D. When can a risk factor be used as a worthwhile screening test?. BMJ 319 (1999) 1562-1565
28. Yamada Y., Matsuo H., Segawa T., et al. Assessment of the genetic component of hypertension. Am. J. Hypertens. 19 (2006) 1158-1165
29. Yang Q., Khoury M.J., Botto L., and Friedman J.M. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am. J. Hum. Genet. 72 (2003) 636-649